Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial

This study is testing whether giving one dose of the drug Tocilizumab one day before a stem cell transplant can safely and effectively prevent a serious complication called graft versus host disease (GVHD). GVHD occurs when the transplanted donor cells attack the patient's body. This is a randomised trial, meaning some participants will receive Tocilizumab and others will receive a placebo (inactive treatment). You may be eligible if: - You are between 18 and 70 years old - You have acute leukaemia in remission or myelodysplasia - You are having a stem cell transplant from a matched donor (related or unrelated) - Your organ function is adequate for transplant - Your ECOG performance status is 2 or below - You have a life expectancy of more than 3 months You may NOT be eligible if: - You are pregnant or breastfeeding - You have HIV, hepatitis C, or active hepatitis B - You have had a solid tumour (other than certain treated skin cancers) within the past 2 years - You have an active serious infection or unstable heart condition - You have a history of bowel perforation or complicated diverticulitis - You have liver cirrhosis - You are allergic to Tocilizumab or similar medicines - Your donor is an identical twin Talk to your doctor about whether this trial might be right for you.